PrecisionBiotics (PB) is delighted to be attending the Groupe Français de Neuro Gastroenterologie Annual Meeting. This year’s meeting features a rich programme focusing on the role of the microbiota in functional GI diseases, nutrition and irritable bowel syndrome.
Following on from the widespread endorsement of 35624™ culture by healthcare professionals in the US and Canada, and the success of its Alflorex® product in the Irish market ,where it has become the market leader in less than 2 years, PresicionBiotics has begun to rollout Alflorex across Europe and will showcase its ground-breaking research to French healthcare professionals at the GFNG annual meeting. 35624™ culture was co-developed by scientists and gastroenterologists at PrecisionBiotics Ltd and the APC Microbiome Institute at University College Cork, one of the world’s leading institutions in human microbiome and gut health research.
PrecisionBiotics is committed to ongoing research and the development and the production of evidence based supplements that both healthcare professionals and customers can believe in. PrecisionBiotics Founder, Scientist and CEO, Barry Kiely, Technical Director, Eileen Murphy and International Business Development Director, Alexandre Lepage will attend the GFNG event to introduce the company’s latest research and to answer any questions. Visit the PrecisionBiotics stand at the GFNG event or contact PrecisionBiotics at email@example.com for further information.
The GFNG event will run from Thursday the 23rd to Friday the 24th of June 2016 in Lyon, France.
To find out more about the research behind Alflorex and 35624™ culture please see a list of published articles and papers here